|
Select publications
Anderson GL et al; Women’s Health Initiative Steering Committee. Effects of conjugated
equine estrogen in postmenopausal women with hysterectomy: The Women’s Health
Initiative randomized controlled trial. JAMA 2004;291(14):1701-12. Abstract
Burstein HJ et al. Optimizing endocrine therapy in postmenopausal women with early
stage breast cancer: A decision analysis for biological subsets of tumors. Proc ASCO 2005;Abstract 529.
Chlebowski RT et al. Dietary fat reduction in postmenopausal women with primary
breast cancer: Phase III Women’s Intervention Nutrition Study (WINS). Proc ASCO 2005;Abstract 10.
Coombes RC et al; Intergroup Exemestane Study. A randomized trial of exemestane after
two to three years of tamoxifen therapy in postmenopausal women with primary
breast cancer. N Engl J Med 2004;350(11):1081-92. Abstract
Cuzick J, Howell A. Optimal timing of the use of an aromatase inhibitor in the
adjuvant treatment of postmenopausal hormone receptor-positive breast cancer. Proc
ASCO 2005;Abstract 658.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy
and hormonal therapy for early breast cancer on recurrence and 15-year survival: An
overview of the randomised trials. Lancet 2005;365(9472):1687-717. Abstract
Gnant M et al. Zoledronic acid effectively counteracts cancer treatment induced bone
loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine
treatment with goserelin plus anastrozole versus goserelin plus tamoxifen — Bone
density subprotocol results of a randomized multicenter trial (ABCSG-12). San
Antonio Breast Cancer Symposium 2004;Abstract 6.
Goss PE et al. A randomized trial of letrozole in postmenopausal women after
f ive years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract
Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen,
Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for
breast cancer. Lancet 2005;365(9453):60-2. Abstract
Jakesz R et al; ABCSG and the GABG. Benef its of switching postmenopausal women
with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant
tamoxifen: Combined results from 3,123 women enrolled in the ABCSG Trial 8 and
the ARNO 95 Trial. San Antonio Breast Cancer Symposium 2004;Abstract 2.
Jakesz R et al. Switching of postmenopausal women with endocrine-responsive early
breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of
ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366(9484):455-62. Abstract
Rossouw JE et al. Risks and benef its of estrogen plus progestin in healthy postmenopausal
women: Principal results from the Women’s Health Initiative randomized
controlled trial. JAMA 2002;288(3):321-33. Abstract
Shumaker SA et al; WHIMS Investigators. Estrogen plus progestin and the incidence
of dementia and mild cognitive impairment in postmenopausal women: The
Women’s Health Initiative Memory Study: A randomized controlled trial. JAMA 2003;289(20):2651-62. Abstract
Shumaker SA et al. Conjugated equine estrogens and incidence of probable dementia
and mild cognitive impairment in postmenopausal women: Women’s Health
Initiative Memory Study. JAMA 2004;291(24):2947-58. Abstract
Thürlimann BJ et al. BIG 1-98: Randomized double-blind phase III study to evaluate
letrozole (L) vs tamoxifen (T) as adjuvant endocrine therapy for postmenopausal
women with receptor-positive breast cancer. Proc ASCO 2005;Abstract 511.
|
